US 12,233,128 B2
Degraders that target ALK and therapeutic uses thereof
Nathanael S. Gray, Boston, MA (US); John M. Hatcher, Boston, MA (US); Chelsea E. Powell, Brookline, MA (US); and Pasi A. Janne, Needham, MA (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Appl. No. 17/278,093
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
PCT Filed Sep. 26, 2019, PCT No. PCT/US2019/053125
§ 371(c)(1), (2) Date Mar. 19, 2021,
PCT Pub. No. WO2020/069106, PCT Pub. Date Apr. 2, 2020.
Claims priority of provisional application 62/895,693, filed on Sep. 4, 2019.
Claims priority of provisional application 62/737,533, filed on Sep. 27, 2018.
Prior Publication US 2022/0409731 A1, Dec. 29, 2022
Int. Cl. A61K 47/54 (2017.01); A61K 47/55 (2017.01)
CPC A61K 47/555 (2017.08) [A61K 47/55 (2017.08)] 7 Claims
 
1. A compound, which is:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or stereoisomer thereof.